(NasdaqGM:HROW), NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its […]

(NASDAQ:LKFN), WARSAW, Ind., Oct. 27, 2025 (GLOBE NEWSWIRE) — Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported net income of $26.4 million for the three months ended September 30, 2025, which represents an increase of $3.1 million, or 13%, compared with net income of $23.3 million for the three

(NasdaqGM:KYMR), KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies KT-579 Phase 1 testing expected to begin in early 2026 WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ:

Montréal, Oct. 27, 2025 (GLOBE NEWSWIRE) — Petal Health, a leader in health technology and improving access to care for patients and providers, and Shoppers Drug Mart are working together to enhance access to patient care through more than 1,700 pharmacy locations across Canada. This partnership was made possible through the CAN Health Network, a

(NASDAQ:DDI), SEOUL, South Korea, Oct. 27, 2025 (GLOBE NEWSWIRE) — DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company“), a leading developer and publisher of digital games on mobile and web-based platforms, announced today that it will release its 2025 third quarter financial results after the market closes on Monday, November 10, 2025, and

(NasdaqGM:AQST), WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2025 and provide an update

(NASDAQ:NMRA), NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits Neumora plans to provide a comprehensive M4 franchise update by mid-2026 WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) — Neumora

(NASDAQ:SNDX), NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 3, 2025. In connection with the earnings release, Syndax's management will host a conference

(NASDAQ:IMTX), Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer (“CPO”) effective October 27, 2025. Ms. Krause brings more than 20 years of

(NasdaqGM:EDAP), EDAP to Participate in the UBS Global Healthcare Conference Company to Host 1×1 Investor Meetings on Monday, November 10th, 2025 AUSTIN, Texas, October 27, 2025 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, and Ken Mobeck, Chief Financial Officer,